Digital RESI JPM Winners

20 Jan

By Megan Rychwa, Investor Research Analyst, LSN

Last week, Life Science Nation wrapped up its second Digital RESI JPM and the first Innovators Pitch Challenge (IPC) of the year. As we prepare for Digital RESI March, we wanted to take this opportunity to announce and celebrate the winners of Digital RESI JPM IPC!

Learn more about the winners below and how their technology is making a difference in the early-stage life science ecosystem. The winners are picked by the votes cast from RESI attendees with exclusive access to the live IPC session and dedicated company landing pages and pitch materials.

The IPC returns March 22-24. Eligible startups can apply until Friday, February 25. All qualifying finalists must purchase a Digital RESI March registration and pay a $800 pitch fee. We accept applications on a rolling basis, so get yours in today!


First Place – Amplified Sciences
Amplified Sciences is a startup life science diagnostics company focused on accurately detecting and pre-empting the risks of debilitating diseases, including lethal cancers and organ loss with R&D operations in Purdue Research Park and research alliances in San Francisco and Boston. The company is developing a portfolio of diagnostic assays for early detection of disease. An ultra-sensitive molecular sensing technology licensed from Purdue operates with novel test-strips that combine with portable instrumentation to form a highly versatile clinical assay platform that can scale to point of care. The lead assay in development is at clinical testing stage and targets early detection of undiagnosed pancreatic cancers. The company closed a Seed round in 2020 which will enable technical and clinical validation of the PanCystPro product and position the company for entry into a commercializable lab-developed test in 2023.

Second Place – OncoXome
OncoXome is an oncology startup whose objective is to bring to patients with advanced cancer an innovative multitarget therapeutic approach hacking cell communication and using gene editing to overcome cancer resistance. They have two platforms: proprietary exosome scalable production and gene editing therapy. Combined, these platforms lead to targeted therapeutic delivery. They first target patients with advanced KRAS mutated lung, colorectal and pancreatic cancers.

Third Place – Prolifagen
Prolifagen is a Start Up company located in Philadelphia and working on a local injectable medicine based on microRNA to regenerate heart muscle damaged by MI and prevent heart failure.  [Approximately 400,000 people develop HF following massive MI yearly in US/EU combined, at a huge cost to society.] They have shown regeneration of cardiac muscle in mice and have early data of regeneration in pigs.  The next milestone will be to define the extent of clinical benefit in a pig model of myocardial infarct, as a steppingstone to clinical trials. They have issued patents in US/EU. So far, their funding has been based on non-dilutive funding from founders and on a phase 1 SBIR grant. They are looking for strategic investment and/or collaboration/licensing.


Digital RESI March Agenda

20 Jan

By Rory McCann, Marketing Manager & Conference Producer, LSN

It’s no secret that January is a time for action – new resolutions, new fundraising campaigns, and, of course, the annual J.P. Morgan Healthcare week – the Olympic torch of life science deal flow. At Life Science Nation, we know that fundraising is a numbers game, and just because January is winding down, doesn’t mean the early-stage ecosystem is. This is why the Redefining Early Stage Investments (RESI) conference series picks up where we left off March 22-24 with a whole new lineup of panels, workshops, pitch sessions, partnering, and more!

Check out our preliminary agenda and visit our website to learn more and see how you can get involved in Digital RESI March! Innovator’s Pitch Challenge applications are open until Friday, February 25, and panel recruitment is ongoing, so if you’re a fit for a panel topic, or if your company is ready to get in front of the right investors for your product and stage of development, contact us to learn more!

Digital RESI March 22-24, 2022 Agenda
Tuesday Wednesday Thursday
10AM EST IPC Session #1 Mental & Behavioral Health Panel IPC Session #8
IPC Session #5
11aM EST Early Stage Therapeutics Panel Age-Tech Devices Panel Precision Medicine Panel
12PM EST First Republic Bank
Burns & Levinson
1PM EST IPC Session #2 IPC Session #6 Cell & Gene Therapy Panel
IPC Session #9
2PM EST Longevity, Health & Wellness Panel Medtech Strategics Panel Defining AI Investment Panel
3PM EST Seed Funds Panel AI Drug Discovery & Development Panel IPC Session #10
IPC Session #3
4PM EST Tales from the Road: AI Innovators on their Fundraising Journey Tales from the Road: Biotech and MedTech Innovators on their Fundraising Journey Tales from the Road: Age-Tech Innovators on their Fundraising Journey
5PM EST IPC Session #4 IPC Session #7 IPC Session #11


RESI’s 2022 Outlook

20 Jan

By Karen Deyo, Director of Investor Research, Israel BD, LSN

2022 is off to a fantastic start with Digital RESI JPM bringing together companies, investors and service providers from 30 countries over 5 continents in a 3-day event full of partnering meetings, investor panels, pitch sessions and workshops.

Life Science Nation has found a formula that works for digital events, and while we look forward to when we can safely return to in-person events, we will continue to offer virtual events to help move the needle in the life sciences. We hope to return to in-person events in June, but will offer options to make our events safe for all.

Make sure to mark your calendars for the following RESI conferences, planned for 2022!

  • Digital RESI, March 22-24 – (virtual)
  • RESI, June 14-16 – San Diego (in-person and virtual)
  • RESI, September 20-22 – Boston (in-person and virtual)
  • RESI, November 15-17 – To be Announced (in-person and virtual)

Registration for Digital RESI March is now open, so make sure to register before the Super Early Bird pricing ends on January 28!


Hot Investor Mandate: VC With Europe Headquarters Invests Up to $20M in Digital Health Companies with Utility for Both Payers and Providers

20 Jan

A venture capital firm headquartered in Europe with offices throughout USA and Europe is investing out of its first fund and makes both seed/venture and growth stage investments ranging from $500k – $20M. The firm typically prefers straight equity investments, but will also consider convertible note financings. The firm has a fairly broad mandate, and invests evenly among enterprise software, fintech, consumer and digital health sectors. The fund’s LPs are large insurance companies, and along with capital, the firm looks to add value by providing portfolio companies direct introductions to these groups to help scale and realize their potential.

The firm plans to have digital health companies make up roughly 25% of its portfolio and will invest in consumer and B2B healthcare IT and tech-enabled health services. It is a requirement that the technology has utility for payers and providers. Some of the firm’s digital health portfolio companies include a behavior change platform that partners with insurers, Accountable Care Organizations (ACO) and Self-insured employers to provide research-based behavioral incentives for members to better manage their chronic conditions.

The firm invests in early-stage companies with annual revenues under $5M as well as growth stage companies with annual revenues exceeding $5M. The firm will consider pre-revenue companies with strong management teams and previously successful entrepreneurs. The firm invests globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Venture and Growth Equity Firm Invests Up to $15M in USA or Europe-Based Medical Device and Digital Health Companies with Strong Clinical Data

20 Jan

A venture and growth capital firm provides expertise and funding to entrepreneurs and companies with global ambitions in life sciences and information technologies. The firm is based in Europe and focuses on early to growth and expansion stage including spin-offs and restarts. The firm prefers to be the lead investor and possibly co-lead. The firm seeks to allocate €7-15 million (in equity) per company through subsequent rounds of investment. The firm seeks to invest in companies that are based in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm seeks to invest in medical devices and digital health. The firm is opportunistic in terms of subsectors and indications. Medical devices with a therapeutic focus are of high interest. The firm seeks growth stage companies with early sales or with products that, at minimum, have regulatory approval (CE mark) and compelling clinical data.

The firm requests a board seat in each portfolio company and generally holds a significant minority stake. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: VC/PE Firm Seeks Commercial Stage Medtech, Life Science Tools, Healthcare Services and More, Typically Invests $10-40M with USA Focus

20 Jan

A private equity/venture capital company founded in 2001 and headquartered in the USA makes growth equity investments ranging from approximately $10 to $40 million over the investment’s lifetime. The firm primarily invests within the United States but is open to consider international investment as well.

The firm is currently looking for commercial stage companies in areas of medical technology and devices, life science instruments and tools, healthcare IT, healthcare services, agriculture and animal health.

The firm only invests in companies with commercial revenue. The firm supports organic growth strategies, which allow for gross profit growth and investment in product pipelines and commercial expansion. The firm looks to take a seat on the company board and prefers to be the lead or sole institutional investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Early-Stage Fund Backed By Major Chinese Companies Seeks Therapeutics, Devices, and Diagnostics Investment Opportunities With China Market Potential

20 Jan

An early stage fund focused on angel investment and incubation in the healthcare field is currently investing from a fund backed by six major Chinese companies. The firm’s typical investment size range from USD 1-1.5 M and is open to leading or co-investing. The firm is currently seeking opportunities in China or US-based companies with a China angle.

The firm is looking for cutting edge platform technologies in sectors including therapeutics, medical devices, and diagnostics. The firm is agnostic to therapeutic indications. In terms of development stage, the firm focuses on startup teams with some preclinical validation.

The firm is looking for strong management teams with sector expertise. The firm aims to bridge between R&D and commercialization with a focus on China-based startup teams or US companies with a China angle. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: